research LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
Search
for
Sort by
Research
810-840 / 1000+ results
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Selective delivery of adapalene to the human hair follicle under finite dose conditions using polymeric micelle nanocarriers
Polymeric micelle nanocarriers deliver adapalene more effectively to hair follicles than commercial products.
research Treatment of alopecia areata in the DEBR model using Cyclosporin A lipid vesicles.
Cyclosporin A vesicles effectively regrow hair and reduce inflammation in alopecia areata.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research Alopecia following oral acyclovir for the treatment of herpes simplex keratitis
A woman lost her hair after taking acyclovir, but it grew back when she stopped the medication.
research Alleviation of alopecia after switching from escitalopram to duloxetine: a case report
Switching from escitalopram to duloxetine helped stop hair loss.
research Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
research Tratamiento con tofacitinib en adolescentes con alopecia areata
Tofacitinib treatment is used for teenagers with alopecia areata.
research New oral anticoagulants and their reversal agents
New oral anticoagulants are safer and easier to use with new reversal agents for bleeding emergencies.
research British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology
Acitretin is effective for severe skin conditions but has significant side effects and requires careful monitoring.
research Effect of interferon therapy on quality of life in patients with chronic hepatitis B
Interferon therapy improves quality of life for chronic hepatitis B patients.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study
Diphenylcyclopropenone treatment helps hair growth in alopecia areata by promoting blood vessel growth and cell survival.
research Oral tofacitinib for the treatment of alopecia areata in pediatric patients
Tofacitinib taken by mouth helps treat hair loss in children.
research A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia
IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.
research 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials
Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.
research 452 Braicitinib treatment reduced the expansion of CD8+ T cells in C3H mice with skin grafts-induced alopecia areata
Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
research 378 Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Baricitinib-loaded EVs promote alopecia areata mouse hair regrowth by reducing JAK-STAT-mediated inflammation and promoting hair follicle regeneration
Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
research Biopharmaceutical Performance of DiluCap: A Line of Functional Excipients Enhancing Dissolution Profiles of Minoxidil, Finasteride, Melatonin, and Naltrexone.
DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.
research Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscle.
research Episodes of Keratitis during Treatment with Baricitinib for Alopecia Areata
Baricitinib for alopecia areata may rarely cause eye issues like keratitis.
research Efficacy, safety and tolerability of dutasteride in male patients with male pattern hair Loss
research Dissecting cellulitis of the scalp successfully treated with infliximab
Infliximab was effective in treating a scalp condition that did not respond to other treatments.
research Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
Tofacitinib is effective and safe for treating severe alopecia areata.
research The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
Erlotinib can cause unexpected side effects like eyelash growth and scarring.
research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.